fulgent genetics inc - FLGT

FLGT

Close Chg Chg %
16.44 0.38 2.31%

Closed Market

16.82

+0.38 (2.31%)

Volume: 556.23K

Last Updated:

Apr 2, 2026, 4:00 PM EDT

Company Overview: fulgent genetics inc - FLGT

FLGT Key Data

Open

$16.34

Day Range

16.15 - 16.92

52 Week Range

13.46 - 31.04

Market Cap

$525.30M

Shares Outstanding

31.23M

Public Float

20.20M

Beta

0.89

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1.97

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

794.94K

 

FLGT Performance

1 Week
 
7.89%
 
1 Month
 
14.97%
 
3 Months
 
-34.27%
 
1 Year
 
-0.24%
 
5 Years
 
-83.26%
 

FLGT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 3
Full Ratings ➔

About fulgent genetics inc - FLGT

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded by Ming Hsieh on May 13, 2016 and is headquartered in El Monte, CA.

FLGT At a Glance

Fulgent Genetics, Inc.
4399 Santa Anita Avenue
El Monte, California 91731
Phone 1-626-350-0537 Revenue 322.67M
Industry Medical/Nursing Services Net Income -60,513,000.00
Sector Health Services 2025 Sales Growth 13.829%
Fiscal Year-end 12 / 2026 Employees 1,344
View SEC Filings

FLGT Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 2.506
Price to Book Ratio 0.734
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -7.095
Enterprise Value to Sales 1.473
Total Debt to Enterprise Value 0.017

FLGT Efficiency

Revenue/Employee 240,082.589
Income Per Employee -45,024.554
Receivables Turnover 3.522
Total Asset Turnover 0.261

FLGT Liquidity

Current Ratio 6.479
Quick Ratio 6.479
Cash Ratio 3.955

FLGT Profitability

Gross Margin 38.071
Operating Margin -28.232
Pretax Margin -21.702
Net Margin -18.754
Return on Assets -4.899
Return on Equity -5.39
Return on Total Capital -5.403
Return on Invested Capital -5.36

FLGT Capital Structure

Total Debt to Total Equity 0.723
Total Debt to Total Capital 0.718
Total Debt to Total Assets 0.662
Long-Term Debt to Equity 0.516
Long-Term Debt to Total Capital 0.512
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Fulgent Genetics Inc - FLGT

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
618.97M 289.21M 283.47M 322.67M
Sales Growth
-37.64% -53.27% -1.99% +13.83%
Cost of Goods Sold (COGS) incl D&A
258.56M 192.60M 184.22M 199.83M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
36.91M 31.76M 24.93M 24.12M
Depreciation
30.41M 23.91M 16.96M 16.09M
Amortization of Intangibles
6.50M 7.84M 7.96M 8.03M
COGS Growth
+19.02% -25.51% -4.35% +8.47%
Gross Income
360.40M 96.61M 99.25M 122.84M
Gross Income Growth
-53.52% -73.19% +2.73% +23.77%
Gross Profit Margin
+58.23% +33.40% +35.01% +38.07%
2022 2023 2024 2025 5-year trend
SG&A Expense
178.90M 171.91M 173.17M 213.94M
Research & Development
28.91M 41.44M 48.82M 53.91M
Other SG&A
149.99M 130.47M 124.35M 160.03M
SGA Growth
+85.22% -3.91% +0.73% +23.54%
Other Operating Expense
- - - -
-
Unusual Expense
2.98M 120.23M 10.07M 9.93M
EBIT after Unusual Expense
178.53M (195.53M) (83.99M) (101.02M)
Non Operating Income/Expense
6.15M 58.44M 32.03M 31.07M
Non-Operating Interest Income
5.30M 21.10M 31.47M 30.92M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 650.00K 37.00M 75.00K
Interest Expense Growth
- - - +5,592.31%
-
Gross Interest Expense
- 650.00K 37.00M 75.00K
Interest Capitalized
- - - -
-
Pretax Income
184.03M (174.09M) (51.96M) (70.03M)
Pretax Income Growth
-72.83% -194.60% +70.15% -34.78%
Pretax Margin
+29.73% -60.19% -18.33% -21.70%
Income Tax
42.10M 1.15M (8.14M) (8.39M)
Income Tax - Current - Domestic
50.38M (10.31M) (4.55M) (7.43M)
Income Tax - Current - Foreign
- - 148.00K 175.00K
-
Income Tax - Deferred - Domestic
(8.28M) (8.67M) (11.05M) (7.38M)
Income Tax - Deferred - Foreign
- 20.14M 7.31M 6.25M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
141.92M (175.24M) (43.82M) (61.63M)
Minority Interest Expense
(1.48M) (7.41M) (1.11M) (1.12M)
Net Income
143.40M (167.82M) (42.71M) (60.51M)
Net Income Growth
-71.53% -217.03% +74.55% -41.69%
Net Margin Growth
+23.17% -58.03% -15.07% -18.75%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
143.40M (167.82M) (42.71M) (60.51M)
Preferred Dividends
- - - -
-
Net Income Available to Common
143.40M (167.82M) (42.71M) (60.51M)
EPS (Basic)
4.7647 -5.6347 -1.4125 -1.9662
EPS (Basic) Growth
-72.18% -218.26% +74.93% -39.20%
Basic Shares Outstanding
30.10M 29.78M 30.23M 30.78M
EPS (Diluted)
4.6313 -5.6347 -1.4125 -1.9662
EPS (Diluted) Growth
-71.51% -221.67% +74.93% -39.20%
Diluted Shares Outstanding
30.96M 29.78M 30.23M 30.78M
EBITDA
218.41M (43.54M) (48.99M) (66.97M)
EBITDA Growth
-68.39% -119.93% -12.52% -36.71%
EBITDA Margin
+35.29% -15.05% -17.28% -20.76%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 33.667
Number of Ratings 3 Current Quarters Estimate -0.317
FY Report Date 06 / 2026 Current Year's Estimate -1.407
Last Quarter’s Earnings -0.46 Median PE on CY Estimate N/A
Year Ago Earnings 0.42 Next Fiscal Year Estimate -1.485
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 3 3 3 3
Mean Estimate -0.32 -0.25 -1.41 -1.48
High Estimates -0.26 -0.12 -1.28 -1.13
Low Estimate -0.39 -0.35 -1.49 -1.79
Coefficient of Variance -20.90 -47.10 -7.93 -22.53

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 1 1 1
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Fulgent Genetics Inc - FLGT

Date Name Shares Transaction Value
May 20, 2025 Linda Marsh Director 27,641 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Regina E. Groves Director 16,982 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Michael Nohaile Director 19,020 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Michael Nohaile Director 6,311 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Fulgent Genetics Inc in the News